Future studies are needed to determine the appropriate energy needs while using a GLP-1RA
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), including structural analogues of human endogenous GLP-1 (albiglutide, dulaglutide, liraglutide, and semaglutide) and exendin-based agents (efpeglenatide, exenatide, and lixisenatide), are antidiabetic medications that share common glucose-lowering mechanisms, such as augmentation of glucose-induced insulin secretion, suppression of glucagon, and deceleration of gastric emptying (Heuvelman et al., 2020
But the licensed weight-loss landscape will look quite different by this time next year
Observations from various rodent studies indicate there were no visual signs of toxicity
GLOW is not just for athletes or post-surgical patients